Cart
sales@molnova.com
UNC9975
CAS No. 1354030-19-5
UNC9975( —— )
Catalog No. M34459 CAS No. 1354030-19-5
UNC9975 is a beta-inhibitory protein-biased dopamine D(2) receptor agonist with antipsychotic activity and can be used to study neurologic disorders such as schizophrenia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUNC9975
-
NoteResearch use only, not for human use.
-
Brief DescriptionUNC9975 is a beta-inhibitory protein-biased dopamine D(2) receptor agonist with antipsychotic activity and can be used to study neurologic disorders such as schizophrenia.
-
DescriptionUNC9975 is a beta-inhibitory protein-biased dopamine D(2) receptor agonist with antipsychotic activity and can be used to study neurologic disorders such as schizophrenia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1354030-19-5
-
Formula Weight463.4
-
Molecular FormulaC23H28Cl2N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1N=C2NC(OCCCCN3CCN(C=4C=CC=C(Cl)C4Cl)CCC3)=CC=C2CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
FAUC-365
FAUC-365 is a D3 dopamine receptor agonist.
-
CP-226269
CP-226269 is a potent dopamine D4 receptor agonist that regulates calcium flux and has an EC50 value of 32.0 nM. CP 226269 can be used to study neurological disorders such as schizophrenia.
-
GSK598809 hydrochlor...
GSK598809 hydrochloride is a potent, selective, CNS penetrant and orally bioavailable dopamine D3 receptor antagonist with pKi of 8.9; displays >100-fold selectivity over D2 and H1 receptors.
